tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TVRD Stock Latest News

Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
RatingsTvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
4d ago
TVRD
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
PremiumThe Fly
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
12d ago
TVRD
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
PremiumCompany Announcements
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
1M ago
8K
TVRD
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
PremiumThe Fly
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
1M ago
TVRD
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
PremiumRatings
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
3M ago
TVRD
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
PremiumCompany AnnouncementsTvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
3M ago
8K
TVRD
Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
Premium
Company Announcements
Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
3M ago
TVRD
Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics
Premium
Ratings
Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics
3M ago
TVRD
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
PremiumThe Fly
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
3M ago
TVRD
Tvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?
PremiumCompany Announcements
Tvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?
4M ago
TVRD
Tvardi downgraded to Market Perform from Outperform at Raymond James
PremiumThe Fly
Tvardi downgraded to Market Perform from Outperform at Raymond James
4M ago
TVRD
Tvardi Therapeutics Faces Setback in Phase 2 Trial
PremiumCompany Announcements
Tvardi Therapeutics Faces Setback in Phase 2 Trial
4M ago
8K
TVRD
Optimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks
PremiumRatingsOptimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks
4M ago
TVRD
Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays
Premium
The Fly
Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays
4M ago
TVRD
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
4M ago
DG
AMD
Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’
PremiumThe Fly
Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’
4M ago
TVRD
Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe Fly
Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
4M ago
TVRD
Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler
PremiumThe Fly
Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler
4M ago
TVRD
Morning Movers: Bloom Energy surges following $5B investment from Brookfield
PremiumThe Fly
Morning Movers: Bloom Energy surges following $5B investment from Brookfield
4M ago
BE
BX
Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?
PremiumMarket NewsWhy Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?
4M ago
TVRD
Tvardi says benefit of TTI-101 treatment not observed in REVERT trial
Premium
The Fly
Tvardi says benefit of TTI-101 treatment not observed in REVERT trial
4M ago
TVRD
Tvardi Therapeutics initiated with an Overweight at Barclays
Premium
The Fly
Tvardi Therapeutics initiated with an Overweight at Barclays
4M ago
TVRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >